On February 17, 2026, 5AM Venture Management reported selling its entire stake in Praxis Precision Medicines (NASDAQ:PRAX), an estimated $9.01 million trade based on last-disclosed position values. What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, 5AM Venture Management sold its 170,000 shares of Praxis Precision Medicines. The fund now reports no position in PRAX, and the total quarter-end valuation for this holding was reduced by $9.01 million as a re ...

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best hot stocks to buy according to analysts. On February 19, Praxis Precision Medicines reported the financial results for Q4 2025, ending 2025 with $926 million in cash & investments. Following an additional $621 million financing in January, the company’s cash runway is now expected to fund operations into 2028. While R&D expenses rose to $267.1 million for the full year due to intensified clinical activity, the company has also expanded its le ...

Core Insights - B Group Inc. reduced its holdings in Praxis Precision Medicines by 10.0% during Q3, now owning 31,500 shares, which is approximately 1.3% of its portfolio, valued at $1,670,000 [2] - Several large investors have adjusted their positions in Praxis Precision Medicines, with notable increases from MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. (5.1% increase), UBS AM (367.8% increase), and Geode Capital Management (8.1% increase) [3] - Praxis Precision Medicines has a market cap of $8.19 billion, with a PE ratio of -21.84 and a beta of 2.86, indicating high volatility [4] Investor Activity - MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,708 shares valued at $444,000 after a 5.1% increase [3] - UBS AM increased its stake significantly by 367.8%, now holding 87,081 shares worth $3,298,000 [3] - Geode Capital Management owns 451,731 shares valued at $18,997,000 after an 8.1% increase [3] Stock Performance - Shares of Praxis Precision Medicines opened at $293.95, with a 52-week low of $26.70 and a high of $356.00 [4] - The company's 50-day moving average is $312.65, while the 200-day moving average is $206.81 [4] Earnings and Analyst Ratings - The company reported an EPS of ($3.50), missing the consensus estimate of ($3.00) by ($0.50) [4] - Analysts have a consensus rating of "Moderate Buy" with an average price target of $576.12, with three analysts rating it as Strong Buy and thirteen as Buy [5] Company Overview - Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing precision therapies for neurological and psychiatric disorders [6] - The company targets specific ion channels and receptor subtypes to address unmet needs in conditions such as rare epilepsies and treatment-resistant depression [7]

Core Insights - The main focus for the company is the Ulixa treatment for Essential Tremor, which is expected to be a significant driver for growth in the upcoming year [2] - The company has submitted New Drug Applications (NDA) for both Ulixa and Relutrigine, opting for a standard review process instead of a priority review to maintain a strong relationship with the FDA [2] Group 1 - The company anticipates a busy year ahead, primarily driven by the Ulixa treatment [2] - The decision to not request priority review for Ulixa was guided by factors aimed at strengthening the relationship with the FDA [2]

Summary of Praxis Precision Medicines FY Conference Call Company Overview - **Company**: Praxis Precision Medicines (NasdaqGS:PRAX) - **Key Products**: ULYXIA (for essential tremor), relutrigine (for epilepsy) Core Industry Insights - **Market Size**: The addressable market for essential tremor is over 2 million patients at peak, significantly larger than previously anticipated [15][16] - **Regulatory Strategy**: The company opted for a standard review process for ULYXIA instead of a priority review to maintain a strong relationship with the FDA and maximize revenue potential before IRA negotiations begin [15][16] Key Points Discussed 1. **NDA Submission**: The NDA for ULYXIA has been submitted, and the company is not requesting priority review, anticipating a standard review process [7][15] 2. **FDA Relationship**: The company has maintained continuity in its interactions with the FDA, with no significant staff changes in the review team since the end of Phase 2 meetings [19][20] 3. **Titration Schedule**: The NDA submission included a standard titration schedule, with a proposal to allow clinicians to maintain a 20-milligram dose for an extra week if tolerability issues arise [30][34] 4. **Patient Tolerability**: Approximately 30% of patients may experience dizziness, which could lead to discontinuation of the drug; however, the company believes that maintaining the 20-milligram dose could resolve this issue for most patients [32][34] 5. **Pre-Launch Activities**: The company is focusing on disease awareness and prescriber identification to prepare for the ULYXIA launch, targeting over 200,000 patients interested in clinical trials [58][71] 6. **Sales Force Strategy**: The company plans to hire around 300 sales representatives to ensure adequate coverage and demand generation for ULYXIA, rather than starting with a smaller team and scaling up [126][127] 7. **Pricing Strategy**: The pricing for ULYXIA is expected to reflect its innovative nature, with a potential starting point in the mid-range of existing treatments for similar conditions [112][114] 8. **Relutrigine Development**: The company is also preparing for the launch of relutrigine, which is expected to receive priority review, with a PDUFA date likely in Q4 [135] Additional Important Insights - **Market Dynamics**: The company anticipates a large volume of patients seeking treatment for essential tremor, with about 1 million patients seen by neurologists annually for prescriptions [76][77] - **Community Engagement**: The company is focusing on building relationships with both specialized centers and community neurologists to ensure effective patient referrals and education [140][141] - **Future Data Catalysts**: Upcoming data from the POWER1 study for vormatrigine is expected to show significant efficacy, with a target of 30% placebo-adjusted seizure reduction [152][154] - **Ongoing Studies**: The phase 3 study for Elsunersen is progressing well, with an amendment to remove sham controls based on FDA recommendations [160][162] This summary encapsulates the key discussions and strategic insights from the Praxis Precision Medicines FY Conference Call, highlighting the company's focus on regulatory strategy, market preparation, and product development.

Company Overview - Praxis Precision Medicines is a Boston-based biotechnology company focused on developing therapies for neurological and psychiatric disorders with significant unmet medical needs [6] - The company has a robust pipeline of differentiated clinical candidates targeting neuronal imbalance, supported by strategic collaborations and licensing agreements [6] - Praxis aims to deliver first-in-class or best-in-class treatments, positioning itself as a potential leader in the CNS therapeutics market [6] Financial Performance - As of February 17, 2026, Praxis Precision Medicines had a market capitalization of $7 billion and a revenue of $7.46 million for the trailing twelve months (TTM) [4] - The company reported a net income loss of $273.04 million for the TTM [4] - Research and development expenses reached $267.1 million for 2025, with a full-year net loss of $303.3 million [10] Recent Developments - Baker Bros. Advisors increased its stake in Praxis by 437,000 shares during Q4 2025, bringing its total stake to 1.94% of 13F reportable assets under management (AUM) [2][7] - The estimated value of the transaction was $81.38 million, with the post-trade stake valued at $295.48 million due to trading activity and price movements [2] - Praxis shares were priced at $328.04, reflecting a 317.1% increase over the past year, significantly outperforming the S&P 500 by 249.48 percentage points [7] Product Pipeline and Market Potential - Praxis is advancing clinical-stage therapies for CNS disorders, with lead candidates including PRAX-114 for major depressive disorder and PRAX-944 for essential tremor [8] - The company has submitted two New Drug Applications (NDAs) in early 2026 for ulixacaltamide and relutrigine, with management believing that four late-stage assets collectively represent over $20 billion in revenue potential [9] - Praxis ended 2025 with $926.1 million in cash and investments, plus an additional $621 million from a January 2026 offering expected to fund operations into 2028 [9] Investment Considerations - The shift from development stage volatility toward potential commercialization creates a wide dispersion in outcomes, but Baker Bros. appears confident in Praxis [9] - Long-term investors should focus on regulatory timelines, launch execution, and upcoming epilepsy data in the first half of 2026 [11] - The significant stock price increase reflects optimism, but potential delays or negative surprises could impact future performance [11]

Company Overview - Praxis Precision Medicines is a Boston-based biotechnology company focused on developing novel therapies for neurological and psychiatric disorders characterized by neuronal imbalance [6] - The company has a pipeline targeting major depressive disorder, essential tremor, and rare epilepsies, emphasizing precision medicine and targeted treatments [6] - As of February 17, 2026, the company's stock price was $328.04, reflecting a significant increase of 320% over the prior year [8] Financial Performance - The company reported a trailing twelve months (TTM) revenue of $7.46 million and a net income loss of $273.04 million [4] - Praxis ended 2025 with $926 million in cash and investments, supplemented by an additional $621 million in financing in January 2026, extending its financial runway into 2028 [10][11] - Research and development spending for 2025 reached $267 million, indicating a late-stage push across multiple programs [11] Recent Developments - On February 17, 2026, Perceptive Advisors LLC disclosed a purchase of 431,432 shares of Praxis Precision Medicines, valued at approximately $80.34 million, increasing its stake significantly [2] - The quarter-end value of Perceptive Advisors' position in Praxis increased by $505.38 million due to the share purchase and subsequent stock price movement [2] - Praxis has submitted two New Drug Applications (NDAs) to the FDA for ulixacaltamide in essential tremor and relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) [10] Market Position and Strategy - The company operates a biopharmaceutical business model focused on research, clinical development, and commercialization of proprietary drug candidates [9] - Praxis targets healthcare providers and specialists in neurology and psychiatry, aiming to address unmet medical needs in these fields [9] - The recent increase in portfolio weightings for Praxis reflects a transition from a pipeline story to a pending commercial launch, indicating potential for rapid changes in investor sentiment [7]

Group 1 - Praxis Precision Medicines, Inc. reported a wider-than-expected loss for the fourth quarter, posting losses of $3.50 per share, which missed the analyst consensus estimate of $3.08 per share [1] - Following the earnings announcement, Praxis Precision Medicine shares fell 0.1% to trade at $303.00 [1] Group 2 - Wedbush analyst Laura Chico maintained an Underperform rating on Praxis Precision Medicine and raised the price target from $95 to $130 [2] - Truist Securities analyst Joon Lee maintained a Buy rating and raised the price target from $500 to $700 [2] - Baird analyst Joel Beatty maintained an Outperform rating and raised the price target from $275 to $433 [2]

Group 1 - Praxis Precision Medicines reported a wider-than-expected loss of $3.50 per share for the fourth quarter, missing the analyst consensus estimate of $3.08 per share [1] - Following the earnings announcement, Praxis Precision Medicine shares fell 0.1% to trade at $303.00 [1] Group 2 - Wedbush analyst Laura Chico maintained an Underperform rating on Praxis Precision Medicine and raised the price target from $95 to $130 [2] - Truist Securities analyst Joon Lee maintained a Buy rating and raised the price target from $500 to $700 [2] - Baird analyst Joel Beatty maintained an Outperform rating and raised the price target from $275 to $433 [2]

Financial Data and Key Metrics Changes - In Q4 2025, operating expenses totaled $97 million, up from $71.4 million in Q4 2024, with R&D expenses increasing from $56.3 million to $77.5 million and G&A expenses rising from $15.1 million to $19.5 million [17][18] - For the full year 2025, operating expenses reached $326 million, compared to $209 million in 2024, driven by increased spending on clinical programs [17][18] - The company ended Q4 2025 with $926 million in cash and equivalents, a significant increase from $469 million at the end of 2024, bolstered by proceeds from public offerings [18][19] Business Line Data and Key Metrics Changes - The ulixacaltamide program reported positive results from the Essential3 program, leading to an NDA submission for essential tremor, with a potential market of over $10 billion annually [9][10] - The relutrigine program for SCN2A and SCN8A DEEs has an initial addressable population of approximately 10,000 patients, with potential annual revenue estimated at $5 billion [12] - Vormatrigine demonstrated a 58% reduction in seizures at week 1 in the RADIANT phase 2 study, with potential annual revenue exceeding $4 billion [14] Market Data and Key Metrics Changes - The addressable population for ulixacaltamide in the U.S. is estimated at 2 million patients with essential tremor, while the broader DEE population for relutrigine is over 200,000 patients [9][12] - The company is preparing for a significant commercial launch, focusing on disease awareness and inventory management for ulixacaltamide and relutrigine [22][31] Company Strategy and Development Direction - The company aims to transform into a commercial entity, with plans to submit two NDAs and enhance its clinical portfolio in 2026 [5][6] - A comprehensive medical education campaign is planned for the upcoming American Academy of Neurology annual meeting to raise awareness about ulixacaltamide [10][25] - The company is focused on building a strong commercial organization and ensuring sufficient inventory for product launches [22][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming year, highlighting the potential for multiple readouts from the clinical pipeline and the importance of executing pre-commercial activities [16][17] - The company is well-capitalized with a strong balance sheet, expecting to fund operations into 2028 [19] - Management emphasized the importance of understanding the competitive landscape and the unmet needs in CNS disorders [10][12] Other Important Information - The company is planning an R&D day to discuss clinical programs and a commercial day to highlight launch strategies for ulixacaltamide and relutrigine [16] - Elsunersen is being developed for a rare genetic epilepsy, with a potential NDA submission expected next year [15][16] Q&A Session Summary Question: Can you walk us through the pre-commercial activities and cadence throughout 2026? - The company is making key hires and building inventory for strong launches, focusing on disease awareness for ulixacaltamide [22] Question: What additional new data can we expect at AAN? - The company will present about 15 different presentations, focusing on the Essential3 program and clinical data [25] Question: What is the status of alternative titration schedules for ulixacaltamide? - The company has proposed alternative titration schedules to the FDA and is awaiting their decision [29] Question: How much capital allocation should be expected between relutrigine and ulixacaltamide? - More allocation is expected for ulixacaltamide due to its broader market potential [31] Question: What is the review timeline for the NDAs? - The company has requested priority review for relutrigine but not for ulixacaltamide, considering strategic business reasons [43][44] Question: Can we expect long-term follow-up data at AAN? - The company plans to present long-term efficacy data to reinforce the value of ulixacaltamide [51] Question: What are the expectations for the EMBRAVE study? - The EMBRAVE study is expected to provide valuable data, with a focus on safety and efficacy [81][84]